|
Oxaliplatin is a diaminocyclohexane (DACH) platin.
Current status
- Number 6 product of sanofi-aventis
- Indications: 1st line metastatic colorectal cancer (MCRC), 2nd line, adjuvant, neoadjuvant
- Licensees: sanofi-aventis (Eloxatin®), Yakult (Elplat®), Dr Reddy’s Laboratories (Dacotin®), Pfizer (Dacplat®)
- Current licensee sales of $2.23 B
Eloxatin® history
Licensed-in
In 1989, from Nagoya University. It had previously been abandoned by several pharmaceutical companies for toxicity.
Status at in-licensing
Clinical phase I
Debiopharm value added
- Correct assessment of benefit/toxicity ratio.
- Development of product up to file submission in France (Reference Member State)
- 15 patent families covering process, combination, formulation and use
- Continuous life cycle management
Timelines
- European approval obtained in 1996 within seven years of in-licensing
- Record 46 day Food and Drug Administration (FDA) approval in 2002 in the United States
- Launch of the aqueous formulation in 2006
Selected Publications
|
